ATE271385T1 - Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia - Google Patents

Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia

Info

Publication number: ATE271385T1
Authority: AT; Austria
Prior art keywords: cyclooxygenase; inhibitors; treat; prevent neoplasia; neoplasia
Prior art date: 1996-10-15

Application number

AT97911746T

Other languages

English (en)

Inventor

Karen Seibert

Jaime Masferrer

Gary B Gordon

Original Assignee

Searle Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-10-15

Filing date

1997-10-14

Publication date

2004-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21843754&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE271385(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-10-14 Application filed by Searle Llc filed Critical Searle Llc

2004-08-15 Application granted granted Critical

2004-08-15 Publication of ATE271385T1 publication Critical patent/ATE271385T1/de

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
230000009826 neoplastic cell growth Effects 0.000 title abstract 2
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
239000002246 antineoplastic agent Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Thiazole And Isothizaole Compounds (AREA)
Pyridine Compounds (AREA)

AT97911746T 1996-10-15 1997-10-14 Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia ATE271385T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US2849496P	1996-10-15	1996-10-15
PCT/US1997/018670 WO1998016227A1 (en)	1996-10-15	1997-10-14	Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Publications (1)

Publication Number	Publication Date
ATE271385T1 true ATE271385T1 (de)	2004-08-15

Family

ID=21843754

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT97911746T ATE271385T1 (de)	1996-10-15	1997-10-14	Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und verbeugung von neoplasia
AT04011516T ATE399547T1 (de)	1996-10-15	1997-10-14	Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
AT04011516T ATE399547T1 (de)	1996-10-15	1997-10-14	Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia

Country Status (24)

Country	Link
EP (3)	EP1479385B1 (de)
JP (1)	JP2001503395A (de)
KR (1)	KR20000049138A (de)
CN (2)	CN100558356C (de)
AT (2)	ATE271385T1 (de)
AU (1)	AU742645B2 (de)
BR (1)	BR9712314A (de)
CA (1)	CA2267186C (de)
CZ (1)	CZ298022B6 (de)
DE (2)	DE69729946T2 (de)
DK (2)	DK1479385T3 (de)
ES (2)	ES2224222T3 (de)
HU (1)	HU227564B1 (de)
IL (3)	IL128568A0 (de)
NO (1)	NO326822B1 (de)
NZ (3)	NZ506515A (de)
PT (2)	PT1479385E (de)
RO (1)	RO120172B1 (de)
RU (1)	RU2239429C2 (de)
SK (1)	SK284788B6 (de)
TR (1)	TR199900827T2 (de)
TW (1)	TWI235060B (de)
UA (1)	UA67732C2 (de)
WO (1)	WO1998016227A1 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2223154A1 (en)	1995-06-02	1996-12-05	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en)	1998-09-14	2003-01-28	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US20040072889A1 (en)	1997-04-21	2004-04-15	Pharmacia Corporation	Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
NZ333399A (en)	1997-12-24	2000-05-26	Sankyo Co	Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
US6294558B1 (en)	1999-05-31	2001-09-25	Pfizer Inc.	Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US6727238B2 (en)	1998-06-11	2004-04-27	Pfizer Inc.	Sulfonylbenzene compounds as anti-inflammatory/analgesic agents
US20020103141A1 (en) *	1998-12-23	2002-08-01	Mckearn John P.	Antiangiogenic combination therapy for the treatment of cancer
AU2592600A (en) *	1998-12-23	2000-07-31	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20040053900A1 (en) *	1998-12-23	2004-03-18	Pharmacia Corporation	Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US6833373B1 (en)	1998-12-23	2004-12-21	G.D. Searle & Co.	Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6649645B1 (en) *	1998-12-23	2003-11-18	Pharmacia Corporation	Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US20040122011A1 (en) *	1998-12-23	2004-06-24	Pharmacia Corporation	Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US6858598B1 (en)	1998-12-23	2005-02-22	G. D. Searle & Co.	Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP1146789B1 (de) *	1999-01-27	2009-03-18	Cornell Research Foundation, Inc.	Behandlung von mit her-2/neu-überexprimierung einhergehendem krebs
JP2003503360A (ja) *	1999-06-24	2003-01-28	ファルマシアコーポレイション	炎症性疾患の処置のための併用療法
RU2268054C2 (ru) *	1999-07-29	2006-01-20	Амджен Инк.	Сочетанная терапия с использованием пентафторбензолсульфонамидов
AU1529901A (en)	1999-11-22	2001-06-04	Smithkline Beecham Plc	Compounds
AU3653301A (en) *	2000-01-28	2001-08-07	Merck & Co., Inc.	Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
GB0003224D0 (en)	2000-02-11	2000-04-05	Glaxo Group Ltd	Chemical compounds
GB0005357D0 (en)	2000-03-06	2000-04-26	Smithkline Beecham Plc	Compounds
US20020009421A1 (en) *	2000-06-01	2002-01-24	Wilder Karol J.	Therapy following skin injury from exposure to ultraviolet radiation
GB0021494D0 (en)	2000-09-01	2000-10-18	Glaxo Group Ltd	Chemical comkpounds
US7199137B2 (en)	2000-09-21	2007-04-03	Smithkline Beecham Plc	Imidazole derivatives as Raf kinase inhibitors
WO2002039958A2 (en)	2000-11-03	2002-05-23	Tularik Inc.	Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
DE60236273D1 (de)	2001-05-03	2010-06-17	Cornell Res Foundation Inc	Behandlung von krankheiten, die durch hpv verursacht werden
GB0112348D0 (en)	2001-05-19	2001-07-11	Smithkline Beecham Plc	Compounds
GB0112810D0 (en)	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0112802D0 (en)	2001-05-25	2001-07-18	Glaxo Group Ltd	Pyrimidine derivatives
GB0119477D0 (en)	2001-08-09	2001-10-03	Glaxo Group Ltd	Pyrimidine derivatives
AR038957A1 (es)	2001-08-15	2005-02-02	Pharmacia Corp	Terapia de combinacion para el tratamiento del cancer
US20050043409A1 (en) *	2001-10-25	2005-02-24	Chen Ying-Nan Pan	Combinations comprising a selective cyclooxygenase-2 inhibitor
FR2835433B1 (fr) *	2002-02-01	2006-02-17	Richard Lab M	Utilisation de la 1-(-4-chlorobenzoyl)-5methoxy-2-methyl-1h- indole-3acetic 4-(acetylamino)phenylester pour la fabrication d'un medicament destine a inhiber exclusivement la cox2
NZ535951A (en) *	2002-03-15	2006-02-24	Pharmacia Corp	Crystalline parecoxib sodium
AU2003216920A1 (en)	2002-04-08	2003-10-20	Glaxo Group Limited	(2-((2-alkoxy)-phenyl)-cyclopent-1-enyl) aromatic carbo and heterocyclic acid and derivatives
ATE325115T1 (de)	2002-08-19	2006-06-15	Glaxo Group Ltd	Pyrimidinderivate als selektive cox-2-inhibitoren
GB0221443D0 (en)	2002-09-16	2002-10-23	Glaxo Group Ltd	Pyridine derivates
KR100484525B1 (ko) *	2002-10-15	2005-04-20	씨제이 주식회사	이소티아졸 유도체, 그 제조방법 및 약제학적 조성물
GB0225548D0 (en)	2002-11-01	2002-12-11	Glaxo Group Ltd	Compounds
PE20040844A1 (es)	2002-11-26	2004-12-30	Novartis Ag	Acidos fenilaceticos y derivados como inhibidores de la cox-2
SI1611112T1 (sl) *	2003-02-11	2012-12-31	Vernalis (R&D) Limited	Izoksazolne spojine kot inhibitorji vroäśinskih ĺ ok proteinov
GB0308466D0 (en)	2003-04-11	2003-05-21	Novartis Ag	Organic compounds
MX2007009888A (es)	2005-02-17	2007-10-16	Synta Pharmaceuticals Corp	Compuestos para el tratamiento de trastornos proliferativos.
ES2397085T3 (es)	2005-03-08	2013-03-04	Mitsui Norin Co., Ltd	Procedimientos y combinaciones de polifenol-coxib
CU23511B6 (es) *	2006-02-28	2010-04-13	Biorec B V	Combinación farmacéutica para el tratamiento y/o quimiosensibilización de tumores refractarios a drogas anticancerígenas
KR20100122513A (ko) *	2008-07-17	2010-11-22	아사히 가세이 파마 가부시키가이샤	질소 함유 복소환 화합물
EP2318545A1 (de) *	2008-08-22	2011-05-11	Novartis AG	Verwendung eines cox-2-hemmers zur behandlung einer cox-2-bedingten erkrankung bei einem patienten ohne nachweis von mit hepatotoxizität assoziierten hla-allelen
EP3313399A4 (de)	2015-06-29	2019-07-24	NantBio, Inc.	Zusammensetzungen und verfahren der rit1-hemmung

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU33730B (en)	1967-04-18	1978-02-28	Farmaceutici Italia	Process for preparing a novel antibiotic substance and salts thereof
US4012448A (en)	1976-01-15	1977-03-15	Stanford Research Institute	Synthesis of adriamycin and 7,9-epiadriamycin
DE69129611T2 (de) *	1990-08-20	1998-12-17	Eisai Co., Ltd., Tokio/Tokyo	Sulfonamid-Derivate
EP0598753B1 (de)	1991-07-19	1998-03-18	Monsanto Company	Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
US5604260A (en)	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0679157B1 (de)	1993-01-15	1997-11-19	G.D. Searle & Co.	3,4-diarylthiophene und analoga davon, sowie deren verwendung als entzündungshemmende mittel
US5409944A (en)	1993-03-12	1995-04-25	Merck Frosst Canada, Inc.	Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
CA2161789A1 (en)	1993-05-13	1994-11-24	Jacques Yves Gauthier	2-substituted-3,4-diarylthiophene derivatives as inhibitors of cyclooxygenase
US5380738A (en)	1993-05-21	1995-01-10	Monsanto Company	2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
WO1995007276A1 (en) *	1993-09-10	1995-03-16	Eisai Co., Ltd.	Bicyclic heterocyclic sulfonamide and sulfonic ester derivatives
US5344991A (en)	1993-10-29	1994-09-06	G.D. Searle & Co.	1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5434178A (en) *	1993-11-30	1995-07-18	G.D. Searle & Co.	1,3,5 trisubstituted pyrazole compounds for treatment of inflammation
US5466823A (en) *	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
US5475018A (en)	1993-11-30	1995-12-12	G. D. Searle & Co.	1,5-diphenyl pyrazole compounds for treatment of inflammation
DE69422306T4 (de) *	1993-11-30	2000-09-07	G.D. Searle & Co., Chicago	Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzündungen
US5393790A (en)	1994-02-10	1995-02-28	G.D. Searle & Co.	Substituted spiro compounds for the treatment of inflammation
US5486534A (en)	1994-07-21	1996-01-23	G. D. Searle & Co.	3,4-substituted pyrazoles for the treatment of inflammation
AU3201095A (en)	1994-07-27	1996-02-22	G.D. Searle & Co.	Substituted thiazoles for the treatment of inflammation
US5620999A (en)	1994-07-28	1997-04-15	Weier; Richard M.	Benzenesulfonamide subtituted imidazolyl compounds for the treatment of inflammation
US5616601A (en)	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5739166A (en)	1994-11-29	1998-04-14	G.D. Searle & Co.	Substituted terphenyl compounds for the treatment of inflammation
US5686470A (en)	1995-02-10	1997-11-11	Weier; Richard M.	2, 3-substituted pyridines for the treatment of inflammation
US5596008A (en)	1995-02-10	1997-01-21	G. D. Searle & Co.	3,4-Diaryl substituted pyridines for the treatment of inflammation
BR9607035A (pt)	1995-02-13	1997-11-04	Searle & Co	Isoxazois substituidos para o tratamento de inflamação
US5510368A (en)	1995-05-22	1996-04-23	Merck Frosst Canada, Inc.	N-benzyl-3-indoleacetic acids as antiinflammatory drugs
CA2223154A1 (en) *	1995-06-02	1996-12-05	G.D. Searle & Co.	Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
EP0859779A4 (de)	1995-08-31	2000-04-12	Smithkline Beecham Corp	Interleukin-konvertierendes enzym und apoptosis
ATE225343T1 (de)	1995-12-20	2002-10-15	Hoffmann La Roche	Matrix-metalloprotease inhibitoren

1997
- 1997-10-14 DE DE69729946T patent/DE69729946T2/de not_active Expired - Lifetime
- 1997-10-14 SK SK462-99A patent/SK284788B6/sk not_active IP Right Cessation
- 1997-10-14 ES ES97911746T patent/ES2224222T3/es not_active Expired - Lifetime
- 1997-10-14 ES ES04011516T patent/ES2308068T3/es not_active Expired - Lifetime
- 1997-10-14 NZ NZ506515A patent/NZ506515A/en not_active IP Right Cessation
- 1997-10-14 EP EP04011516A patent/EP1479385B1/de not_active Expired - Lifetime
- 1997-10-14 CA CA002267186A patent/CA2267186C/en not_active Expired - Fee Related
- 1997-10-14 IL IL12856897A patent/IL128568A0/xx not_active IP Right Cessation
- 1997-10-14 PT PT04011516T patent/PT1479385E/pt unknown
- 1997-10-14 EP EP08159064A patent/EP1977749A1/de not_active Withdrawn
- 1997-10-14 PT PT97911746T patent/PT932402E/pt unknown
- 1997-10-14 AT AT97911746T patent/ATE271385T1/de active
- 1997-10-14 DK DK04011516T patent/DK1479385T3/da active
- 1997-10-14 CN CNB2005100062282A patent/CN100558356C/zh not_active Expired - Fee Related
- 1997-10-14 CZ CZ0117199A patent/CZ298022B6/cs not_active IP Right Cessation
- 1997-10-14 HU HU9904221A patent/HU227564B1/hu not_active IP Right Cessation
- 1997-10-14 KR KR1019990703225A patent/KR20000049138A/ko not_active Withdrawn
- 1997-10-14 UA UA99052704A patent/UA67732C2/uk unknown
- 1997-10-14 TW TW090122228A patent/TWI235060B/zh not_active IP Right Cessation
- 1997-10-14 TR TR1999/00827T patent/TR199900827T2/xx unknown
- 1997-10-14 WO PCT/US1997/018670 patent/WO1998016227A1/en not_active Ceased
- 1997-10-14 NZ NZ334921A patent/NZ334921A/en not_active IP Right Cessation
- 1997-10-14 DE DE69738815T patent/DE69738815D1/de not_active Expired - Lifetime
- 1997-10-14 DK DK97911746T patent/DK0932402T3/da active
- 1997-10-14 RO RO99-00418A patent/RO120172B1/ro unknown
- 1997-10-14 JP JP51859198A patent/JP2001503395A/ja not_active Ceased
- 1997-10-14 EP EP97911746A patent/EP0932402B1/de not_active Expired - Lifetime
- 1997-10-14 BR BR9712314-5A patent/BR9712314A/pt not_active Application Discontinuation
- 1997-10-14 AT AT04011516T patent/ATE399547T1/de active
- 1997-10-14 AU AU49048/97A patent/AU742645B2/en not_active Ceased
- 1997-10-14 RU RU99110192/15A patent/RU2239429C2/ru not_active IP Right Cessation
- 1997-10-14 IL IL15450197A patent/IL154501A0/xx not_active IP Right Cessation
- 1997-10-14 CN CNB971987548A patent/CN1332661C/zh not_active Expired - Fee Related
1999
- 1999-04-15 NO NO19991793A patent/NO326822B1/no not_active IP Right Cessation
2001
- 2001-02-07 NZ NZ509755A patent/NZ509755A/xx not_active IP Right Cessation
2004
- 2004-12-16 IL IL16581604A patent/IL165816A0/xx unknown

Also Published As

Publication number	Publication date
CN100558356C (zh)	2009-11-11
EP0932402A1 (de)	1999-08-04
TWI235060B (en)	2005-07-01
HUP9904221A3 (en)	2000-12-28
EP1479385B1 (de)	2008-07-02
CZ298022B6 (cs)	2007-05-30
ES2224222T3 (es)	2005-03-01
HK1025518A1 (en)	2000-11-17
BR9712314A (pt)	1999-08-31
AU742645B2 (en)	2002-01-10
PT932402E (pt)	2004-11-30
EP1479385A1 (de)	2004-11-24
CN1332661C (zh)	2007-08-22
UA67732C2 (uk)	2004-07-15
DE69729946D1 (de)	2004-08-26
DK1479385T3 (da)	2008-08-04
EP0932402B1 (de)	2004-07-21
KR20000049138A (ko)	2000-07-25
CA2267186C (en)	2002-05-14
RU2239429C2 (ru)	2004-11-10
IL154501A0 (en)	2003-09-17
NZ509755A (en)	2002-09-27
NZ334921A (en)	2001-03-30
ATE399547T1 (de)	2008-07-15
DE69729946T2 (de)	2005-01-20
CN1660083A (zh)	2005-08-31
NZ506515A (en)	2002-05-31
IL165816A0 (en)	2006-01-15
TR199900827T2 (xx)	1999-07-21
WO1998016227A1 (en)	1998-04-23
CZ117199A3 (cs)	1999-07-14
NO326822B1 (no)	2009-02-23
PT1479385E (pt)	2008-09-02
RO120172B1 (ro)	2005-10-28
HUP9904221A2 (hu)	2000-09-28
CN1244122A (zh)	2000-02-09
AU4904897A (en)	1998-05-11
ES2308068T3 (es)	2008-12-01
NO991793D0 (no)	1999-04-15
IL128568A0 (en)	2000-01-31
HU227564B1 (en)	2011-08-29
DE69738815D1 (de)	2008-08-14
CA2267186A1 (en)	1998-04-23
EP1977749A1 (de)	2008-10-08
NO991793L (no)	1999-04-15
SK284788B6 (sk)	2005-11-03
JP2001503395A (ja)	2001-03-13
SK46299A3 (en)	2000-03-13
DK0932402T3 (da)	2004-11-08

Legal Events

Date

Code

Title

Description

2005-03-15

UEP

Publication of translation of european patent specification

Ref document number: 0932402

Country of ref document: EP

Publication	Publication Date	Title
ATE399547T1 (de)	2008-07-15	Verwendung von cyclooxygenase-2 inhibitoren zur behandlung und vorbeugung von neoplasia
ATE179610T1 (de)	1999-05-15	Zusammensetzung zur behandlung ovarieller östrogenabhängiger krankheiten
DE60112766D1 (de)	2005-09-22	Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
FI956119A0 (fi)	1995-12-19	Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina
UA26213C2 (uk)	1999-07-19	Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE59409312D1 (de)	2000-05-31	Imidazopyridine und ihre anwendung zur behandlung von magen-darm krankheiten
DE60013266D1 (de)	2004-09-30	Steroidnitrate zur behandlung von oxidativen schädigungen und endothelialer dysfunktion
DE69918972D1 (de)	2004-09-02	Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE69707372D1 (de)	2001-11-22	Verwendung eines Phosphorsäurediesters zur Herstellung eines Arzneimittels zur Behandlung von Akne
DE3854121D1 (de)	1995-08-10	Arzneimittelzusammensetzungen zur behandlung von psoriasis.
ATE180669T1 (de)	1999-06-15	Verwendung von pregnanderivaten zur behandlung von tumoren
ATE225171T1 (de)	2002-10-15	Aminosäurederivate zur behandlung von schlaganfall
DE69816244D1 (de)	2003-08-14	Verwendung von 2-Aryl-3-aroylbenzo(b)thiophene zur Behandlung des Oestrogenenthaltungssyndroms
DE69917074D1 (de)	2004-06-09	Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
ATE262330T1 (de)	2004-04-15	Verwendung eines nitroxids oder seiner prodrugs zur prophylaktischen und therapeutischen behandlung von krebs
ATE332697T1 (de)	2006-08-15	Cyanidinmischung zur behandlung von dickdarmkrebs
ATE315387T1 (de)	2006-02-15	Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
ATE271384T1 (de)	2004-08-15	Arylnitron therapeutische mittel zur behandlung von entzündlichen darmerkrankungen
DE69808607D1 (de)	2002-11-14	Verfahren zur verwendung von cyclooxygenase-2 hemmern zur behandlung und vorbeugung der demenz
DE60215947D1 (de)	2006-12-21	Pyridin-2-yl-methylamin-derivate zur behandlung von opiatsucht
ATE292970T1 (de)	2005-04-15	Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DE60218726D1 (de)	2007-04-19	Verwendung von 4-oxo-butansäure derivaten zur behandlung der entzündung